VIDEO: Finerenone studies show ‘consistent data’ on benefits in HF outcomes

ByErin Michael

Javed Butler, MD, discusses interesting presentations in HF at the American Heart Association Scientific Sessions.

Butler, the Patrick H. Lehan Chair in Cardiovascular Research, professor and chairman of the department of medicine at the University of Mississippi Medical Center, said the FIGARO-DKD and FIDELITY-DKD trials examining finerenone (Kerendia, Bayer) and HF outcomes.

Butler said these presentations showed “consistent data” that patients with and without HF at baseline “both substantially improved their heart failure outcomes.”

He added that this “bodes well for the finerenone HFpEF study, which is ongoing. We’ll see, that’s a big question in people’s minds.”

References:

Butler J, et al. Where should new heart failure guidelines change in 2021?

Filippatos G, et al. Finerenone in patients with stage 1-4 chronic kidney disease and type 2 diabetes: A secondary analysis of heart failure from the FIGARO-DKD trial. Both presented at: American Heart Association Scientific Sessions; Nov. 13-15, 2021 (virtual meeting).

Published by:

Sources/Disclosures

Collapse

Source: Healio Interview

Disclosures: Butler reports receiving consultant fees from Abbott, Adrenomed, Amgen, Array, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CVRx, G3 Pharmaceutical, Impulse Dynamics, Innolife, Janssen, LivaNova, Luitpold, Medtronic, Merck, Novartis, Novo Nordisk, Roche and Vifor, and serving on the speakers bureau for AstraZeneca, Boehringer Ingelheim-Lilly, Janssen and Novartis.

Take Homes in Heart Failure

Read more

VIDEO: Finerenone studies show ‘consistent data’ on benefits in HF outcomes

References:

Related Content